CARDIFF ONCOLOGY, INC. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
CARDIFF ONCOLOGY, INC. (CRDF) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $432.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2026-02-24
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2025 was $432.00K, a 11.48% decline from fiscal 2024.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2024 was $488.00K, a 45.90% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $902.00K, a 63.11% increase from fiscal 2022.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was $553.00K, a 70.15% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $432.00K 10-K · filed 2026-02-24 | |
| 2024-12-31 | $488.00K 10-K · filed 2026-02-24 | $1.07M 10-K · filed 2025-02-27 |
| 2023-12-31 | $902.00K 10-K · filed 2025-02-27 | |
| 2022-12-31 | $553.00K 10-K · filed 2024-02-29 | |
| 2021-12-31 | $325.00K 10-K · filed 2023-03-02 | |
| 2020-12-31 | $81.00K 10-K · filed 2022-02-24 | |
| 2019-12-31 | $875.00K 10-K · filed 2021-02-25 | |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |